NSE · BETA · Pharmaceuticals
Beta Drugs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹56 Cr with net profit ₹6 Cr — a 10.62% net margin, versus 9.81% the period before.
Shareholding
As of 2026-06-30
- Promoter59.1%
- Public33.65%
- FII1.02%
- DII6.23%
7,359 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.7× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #8 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,08,618 Cr | 277.59 | 12.42 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,064 Cr | 197.86 | 15.76 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,393 Cr | 67.55 | 13.02 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,418 Cr | 128.21 | 2.16 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,777 Cr | 68.4 | 2.44 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,614 Cr | 35.44 | 4.6 | 12.98% | 11.5% |
| Hikal Limited | ₹2,688 Cr | 186.32 | 2.25 | 3.03% | -2.88% |
| Beta Drugs Limited(this company) | ₹2,259 Cr | 249.5 | 9.23 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,010 Cr | 41.77 | 6.11 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,332 Cr | 67.96 | 3.2 | 17.67% | 13.66% |
AI analysis
AI-generated · google/gemini-2.5-flashBeta Drugs Limited is listed with a market capitalization of Rs 2473 Cr. The company reported revenue of Rs 368.79 Cr with a profit margin of 10.78%. Earnings per share (EPS) stood at Rs 44.97.
Positives
- +Revenue growth was 22.5%, indicating an increase in sales.
- +The debt-to-equity ratio is 0.43, suggesting a modest level of debt.
- +Return on capital employed (ROCE) is 17.4555%, indicating efficient use of capital.
Negatives
- −The trailing twelve months PE ratio is 273.17, which is high.
- −The company has not disclosed quarterly results since March 2026.
- −FII shareholding declined from an unspecified amount in Aug 2017 to 2.9542% in May 2026.
- −Despite having quarterly results in 2025 and 2026, the EPS for these periods is not provided.
Financial Performance
Beta Drugs Limited achieved revenue of Rs 368.79 Cr, representing a growth of 22.5%. The company's profit margin was 10.78%, leading to an EPS of Rs 44.97. Return on equity (ROE) was 16.95% and return on capital employed (ROCE) was 17.4555%.
Profitability & Returns
The company recorded a profit margin of 10.78%. Return on equity (ROE) was 16.95% and return on capital employed (ROCE) was 17.4555%. The PE ratio stands at 273.17.
Balance Sheet
The company has a debt-to-equity ratio of 0.43. The book value per share is Rs 241.46.
Ownership & Pledges
DIIs held 6.0148% and FIIs held 2.9542%. The public shareholding was 31.9342%. There are no reported promoter share pledges.
Regulatory & Surveillance
There is no information provided regarding the company's inclusion on any surveillance lists.
Data as of — price: 2026-07-30 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.